Abstract:Aim: To observe the immunosuppressive effect of rapamycin eye drops on immunological rejection after high-risk corneal transplantation in rats, and observe the effects of eye drops combined with cyclosporin A. Methods: The experiment was performed at the Animal Laboratory of Liaoning Medical University from December 2004 to March 2005. Totally 50 healthy male SD rats were used as recipients, and 23 female Wistar rats were used as donors. SD rats with corneal vascularization were taken as recipients to establish animal model of high-risk penetrative corneal transplantation. 1 Totally 40 recipients were involved in the result analysis, and randomly assigned into 4 groups, 10 rats in each group. Control group (ophthalmic solution solvent), Rapamycin-treated group (2 g/L rapamycin eye drops), Cyclosporin A-treated group (10 g/L cyclosporin A eye drops), 100 μL every time; Rapamycin and cyclosporin A-treated group (2 g/L rapamycin eye drops 50 μL and 10 g/L cyclosporin A eye drops 50 μL). The animals were given the drugs 4 times every day from the 2nd day after operation, and the animals were administered until rejection. 2 The corneal grafts were inspected by slit-lamp microscope clinically. The sum of turbidness, hydroncus and new vessels was as rejection reaction index on that day. When the index ≥ 5 or turbidness of grafts reached 3, it was considered the occurrence of rejection reaction. The corneal survival time was recorded. 3 At day 14 after corneal transplantation, 4 animals in each group were randomly selected for corneal histological test. Results: Totally 40 rats were involved in the result analysis. 1 Comparison of corneal survival time in each group: The corneal survival time in the Control group, Rapamycin-treated group, Cyclosporin A-treated group and Rapamycin and cyclosporin A-treated group was (7.67±1.03, 16.67±1.63, 15.50±2.43, 21.33±2.94) days, respectively. The survival time of the corneal grafts in each treated group was significantly prolonged as compared with the Control group (P < 0.01). The combined medicine group was significantly superior to the simple medicine group (P < 0.01). There was no significant difference between the Rapamycin-treated group and Cyclosporin A-treated group (P > 0.05). 2 Corneal histomorphology change at day 14 after corneal transplantation in each group: The inflammation cells, neovascularity and edema of the corneal grafts in each treated group were significantly fewer than those in the Control group, and there were no inflammation cells and neovascularity in the center of the grafts in combined treated group. Conclusion: 2 g/L rapamycin eye drops can markedly prolong the survival time of corneal grafts in high-risk corneal transplantation. The combined therapy with 10 g/L cyclosporin A eye drops produces synergistic effect, and the therapeutic efficacy is superior to rapamycin or cyclosporin A alone.

Rapamycin Antagonizes Angiogenesis and Lymphangiogenesis Through Myeloid-Derived Suppressor Cells in Corneal Transplantation

MicroRNA-21 mediates the rapamycin-induced suppression of endothelial proliferation and migration.

Pretreatment of Rapamycin Before Allogenic Corneal Transplant Promotes Graft Survival Through Increasing CD4(+)CD25(+)Foxp3(+) Regulatory T Cells.

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Exosomal miR‐181d‐5p Derived from Rapamycin‐Conditioned MDSC Alleviated Allograft Rejection by Targeting KLF6

Influence of rapamycin combined with cyclosporin A eye drops on rejection reaction after high-risk corneal transplantation in rats

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1

Immunomodulation of T Cell-Mediated Alloimmunity by Proximity to Endothelial Cells under the Mammalian Target of Rapamycin Blockade.

Experimental studies of rapamycin eye drops on the prevention of penetrating keratoplasty rejection in a rat model

Enhanced autophagy alleviated corneal allograft rejection via inhibiting NLRP3 inflammasome activity

Rapamycin Immunomodulation Utilizes Time-Dependent Alterations of Lymph Node Architecture, Leukocyte Trafficking, and Gut Microbiome

Rapamycin Liposomes Targeted to Lymph Nodes Inhibit Dendritic Cell Maturation for the Treatment of Transplant Rejection

RapaLink-1 Outperforms Rapamycin in Alleviating Allogeneic Graft Rejection by Inhibiting the Mtorc1-4E-bp1 Pathway in Mice.

Effects of rapamycin on number and activity of endothelial progenitor cells

Effects of rapamycin on DC-SIGN expression and biological functions in DC.

Lentivirus-mediated IL-10-expressing Bone Marrow Mesenchymal Stem Cells promote corneal allograft survival via upregulating lncRNA 003946 in a rat model of corneal allograft rejection

Mtor Inhibitor Rapamycin Induce Polymorphonuclear Myeloid-Derived Suppressor Cells Mobilization and Function in Protecting Against Acute Graft-Versus-host Disease after Bone Marrow Transplantation

Effect of locally administered rapamycin and cyclosporin A on penetrating keratoplasty rejection rat model

Rapamycin increases the incidence of neuropsychiatric illness in kidney transplant patients through the suppression of neural stem cells

Limited Efficacy of Rapamycin Monotherapy in Vascularized Composite Allotransplantation.

Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages